{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:36:09Z","timestamp":1791513369284,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH123396"],"award-info":[{"award-number":["R01MH123396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI157855"],"award-info":[{"award-number":["T32AI157855"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL152903"],"award-info":[{"award-number":["K23HL152903"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AG084415"],"award-info":[{"award-number":["K23AG084415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Emory Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in the highest HIV burden areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective review of PWH who initiated LA-ART (cabotegravir\/rilpivirine [CAB\/RPV] \u00b1 lenacapavir [LEN] \u00b1 ibalizumab [IBA]) with viremia (\u226550 c\/mL) at a Ryan White-funded program in the urban South between 14 April 2021 and 31 August 2024. Among PWH who received \u22653 LA-CAB\/RPV injections through end of follow-up (31 December 2024), achieving VS (&amp;lt;50 c\/mL) was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-one PWH with viremia initiated LA-ART. Among them, 93% identified as Black, 40% were cis-\/trans-women, the median (Q1\u2013Q3) age was 38 (30\u201349) years, and the median income was $25K\/year ($20\u201333K\/year). The median (Q1\u2013Q3) time since HIV diagnosis was 15.5 (8.8\u201320.5) years, and 46% had prior opportunistic conditions. At LA-ART initiation (56 CAB\/RPV; 22 CAB \u00b1 RPV + LEN; 3 CAB \u00b1 RPV + LEN + IBA), the median (Q1\u2013Q3) viral load was 4.0 (2.9\u20134.8) log10 and CD4 + 186 (62\u2013420) cells\/\u03bcL. Of 79 PWH who remained engaged, 73 (92%) achieved VS after a median (Q1\u2013Q3) of 1 (1\u20132) injection, with CD4 rise to 353 (187\u2013501) cells\/\u03bcL. Otherwise, 2 had virologic failure with drug resistance; 4 had persistent viremia without resistance (&amp;gt;200 c\/mL [n = 2]; 50\u2013200 c\/mL [n = 2]). Of 645 LA-CAB\/RPV injections (500 Q4wk; 145 Q8wk), 635 (98%) were administered on-time; all LEN (43\/43) and IBA (37\/37) administrations occurred on-time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the largest southern US cohort of PWH with viremia initiating LA-ART, 92% achieved VS despite significant barriers to care and disease burden, underscoring LA-ART as a tool to help achieve Ending the HIV Epidemic goals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf425","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:41:21Z","timestamp":1753962081000},"page":"564-574","source":"Crossref","is-referenced-by-count":14,"title":["Long-Acting Cabotegravir\/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-9769","authenticated-orcid":false,"given":"Jonathan A","family":"Colasanti","sequence":"first","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]},{"name":"Department of Global Health, Emory University Rollins School of Public Health , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-4298","authenticated-orcid":false,"given":"Amalia","family":"Aldredge","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-4969","authenticated-orcid":false,"given":"Larisa V","family":"Niles-Carnes","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudiah","family":"Ochieng","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyasha","family":"Pareek","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Robinson","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Anderson","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Castaneda","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Spralling","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4540-1433","authenticated-orcid":false,"given":"Bradley L","family":"Smith","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeri","family":"Sumitani","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Paul Leue","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-0465","authenticated-orcid":false,"given":"Caitlin A","family":"Moran","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5999-6655","authenticated-orcid":false,"given":"Meredith","family":"Lora","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-2276","authenticated-orcid":false,"given":"Wendy S","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-5454","authenticated-orcid":false,"given":"Lauren F","family":"Collins","sequence":"additional","affiliation":[{"name":"Ponce De Leon Center, Grady Health System , Atlanta, Georgia ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2026043013130696500_ciaf425-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026043013130696500_ciaf425-B2","author":"Highlights of Prescribing Information- CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]"},{"key":"2026043013130696500_ciaf425-B3","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2026043013130696500_ciaf425-B4","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96\u2013week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2026043013130696500_ciaf425-B5","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"key":"2026043013130696500_ciaf425-B6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)","volume":"14","author":"Chounta","year":"2021","journal-title":"Patient"},{"key":"2026043013130696500_ciaf425-B7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"key":"2026043013130696500_ciaf425-B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/COH.0000000000000577","article-title":"Challenges of reaching 90-90-90 in the Southern United States","volume":"14","author":"Colasanti","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"2026043013130696500_ciaf425-B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2024.06.002","article-title":"Human immunodeficiency virus in the south: an epidemic within an epidemic","volume":"38","author":"Saldana","year":"2024","journal-title":"Infect Dis Clin North Am"},{"key":"2026043013130696500_ciaf425-B10","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026043013130696500_ciaf425-B11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026043013130696500_ciaf425-B12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026043013130696500_ciaf425-B13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2025.0109","article-title":"HIV viral suppression with use of long-acting antiretroviral therapy in people with and without initial viremia","volume":"333","author":"Spinelli","year":"2025","journal-title":"JAMA"},{"key":"2026043013130696500_ciaf425-B14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"Brock","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026043013130696500_ciaf425-B15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"IAS-USA Treatment guidelines panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"2026043013130696500_ciaf425-B16","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2026043013130696500_ciaf425-B17","doi-asserted-by":"crossref","first-page":"13596535231201162","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective","volume":"28","author":"Carr","year":"2023","journal-title":"Antivir Ther"},{"key":"2026043013130696500_ciaf425-B18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"2026043013130696500_ciaf425-B19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026043013130696500_ciaf425-B20","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","article-title":"Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial","volume":"11","author":"Gandhi","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026043013130696500_ciaf425-B21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/apc.2023.0061","article-title":"The CARES program: improving viral suppression and retention in care through a comprehensive team-based approach to care for people with HIV and complex psychosocial needs","volume":"37","author":"Sweitzer","year":"2023","journal-title":"AIDS Patient Care STDS"},{"key":"2026043013130696500_ciaf425-B22","doi-asserted-by":"crossref","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","article-title":"Early experience implementing long-acting injectable cabotegravir\/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan white-funded clinic in the US South","volume":"9","author":"Collins","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026043013130696500_ciaf425-B23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/aid.2024.0007","article-title":"Early implementation and outcomes among people with HIV who accessed long-acting injectable cabotegravir\/rilpivirine at two Ryan white clinics in the U.S. South","volume":"40","author":"Haser","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026043013130696500_ciaf425-B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09350-8","article-title":"Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net hospital-based primary care center in U.S. South","author":"Baker","year":"2025","journal-title":"J Gen Intern Med"},{"key":"2026043013130696500_ciaf425-B25","doi-asserted-by":"crossref","first-page":"ofaf096","DOI":"10.1093\/ofid\/ofaf096","article-title":"Enhancing hepatitis B virus vaccine uptake and immunity through long-acting antiretroviral therapy programmatic synergy in the US South","volume":"12","author":"Ochieng","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026043013130696500_ciaf425-B26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026043013130696500_ciaf425-B27","doi-asserted-by":"crossref","first-page":"ofac312","DOI":"10.1093\/ofid\/ofac312","article-title":"Effect of social determinants of health on uncontrolled human immunodeficiency virus (HIV) infection among persons with HIV in San Francisco, California","volume":"9","author":"Melo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026043013130696500_ciaf425-B28","doi-asserted-by":"crossref","first-page":"23259582241251728","DOI":"10.1177\/23259582241251728","article-title":"Assessing the impact of social determinants of health on HIV care engagement in the Southern United States: a cross-sectional study","volume":"23","author":"Sohail","year":"2024","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2026043013130696500_ciaf425-B29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med."},{"key":"2026043013130696500_ciaf425-B30","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s10461-022-03958-1","article-title":"Prioritization of evidence-based and evidence-informed interventions for retention in medical care for persons with HIV","volume":"27","author":"Collins","year":"2023","journal-title":"AIDS Behav"},{"issue":"Suppl 2","key":"2026043013130696500_ciaf425-B31","doi-asserted-by":"crossref","first-page":"ofad500.1443","DOI":"10.1093\/ofid\/ofad500.1443","article-title":"1608. Real-world effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment-experienced individuals: two years of data from the OPERA\u00ae cohort","volume":"10","author":"Sension","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026043013130696500_ciaf425-B32","author":"Hu"},{"key":"2026043013130696500_ciaf425-B33","doi-asserted-by":"crossref","first-page":"e26394","DOI":"10.1002\/jia2.26394","article-title":"Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir\/rilpivirine among early adopters in three U.S. clinics","volume":"27","author":"Christopoulos","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026043013130696500_ciaf425-B34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAD.0000000000003760","article-title":"A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine","volume":"38","author":"Ripamonti","year":"2024","journal-title":"AIDS"},{"key":"2026043013130696500_ciaf425-B35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"issue":"Suppl 1","key":"2026043013130696500_ciaf425-B36","doi-asserted-by":"crossref","first-page":"e26282","DOI":"10.1002\/jia2.26282","article-title":"Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP project","volume":"27","author":"Nguyen","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026043013130696500_ciaf425-B37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/apc.2023.0248","article-title":"Long-acting injectable antiretrovirals for HIV treatment: a multi-site qualitative study of clinic-level barriers to implementation in the United States","volume":"38","author":"McCrimmon","year":"2024","journal-title":"AIDS Patient Care STDS"},{"key":"2026043013130696500_ciaf425-B38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/cid\/ciae648","article-title":"Policy recommendations to support equitable access to long-acting injectables for HIV prevention and treatment: a policy paper of the Infectious Diseases Society of America and the HIV Medicine Association","volume":"82","author":"Marcus","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026043013130696500_ciaf425-B39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/ciae265","article-title":"Position of the Infectious Diseases Society of America and the HIV Medicine Association on Team-based Infectious Diseases Care and the Roles of Advanced Practice Providers and Clinical Pharmacists","volume":"79","author":"Infectious Diseases Society of America (IDSA)","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026043013130696500_ciaf425-B40","first-page":"2259","article-title":"The HIV workforce in crisis: an urgent need to build the foundation required to end the epidemic","volume":"71","author":"Armstrong","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf425\/63907164\/ciaf425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/564\/63907164\/ciaf425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/564\/63907164\/ciaf425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:13:15Z","timestamp":1777569195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/564\/8220714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf425","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,8,1]]}}}